高危上尿路尿路上皮癌新辅助化疗的生存结局:全国代表性分析
基于美国国家癌症数据库2004至2015年接受肾输尿管切除术的上尿路尿路上皮癌患者,评估新辅助化疗对生存的影响。10,315例符合化疗条件者中仅296例(2.9%)接受新辅助化疗;
要点
- 临床非器官局限性疾病中新辅助化疗组27.1%术后病理降期至器官局限,初始手术组仅1.4%。
核心结论
- 高危非器官局限性上尿路尿路上皮癌患者接受新辅助化疗可提高病理降期率并与总生存改善相关。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库2004至2015年接受肾输尿管切除术的上尿路尿路上皮癌患者,共纳入10,315例符合化疗条件者。
主要发现
- 296例(2.9%)患者术前接受新辅助化疗。
- 多因素分析显示接受新辅助化疗者总生存有统计学显著改善。
- 术前化疗组中临床非器官局限性疾病患者27.1%术后为器官局限性疾病,初始手术组为1.4%。
临床怎么用
- 对高危、临床非器官局限性上尿路尿路上皮癌患者,可考虑术前新辅助化疗以争取病理降期并改善生存。
局限性
- 研究为回顾性数据库分析,新辅助化疗组样本量小(296例,占2.9%),存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the impact of neoadjuvant chemotherapy (NAC) on survival outcomes in a contemporary cohort of patients with in upper tract urothelial carcinoma (UTUC). METHODS: The National Cancer Database was queried from 2004 to 2015 to identify subjects who underwent nephroureterectomy for UTUC. Kaplan-Meier method with log-rank test was performed to compare all-cause mortality between patients who received preoperative chemotherapy to those who did not at each pathologic (p) TNM stage group: T1-4N0, N+, and M+ disease. Associations for all-cause mortality were identified using an adjusted Cox regression analysis. RESULTS: A total of 10,315 chemoeligible subjects were included in the analysis. A total of 296 (2.9%) of patients received NAC prior to NU. Kaplan-Meier survival curves of the entire cohort demonstrated an overall survival advantage associated with administration of NAC (P = .017). Stratified by clinical staging, subjects with nonorgan-confined tumors had improved overall survival outcomes with NAC administration (P = .012). On multivariate analysis there was a statistically significant improvement in overall survival between in patients who received NAC. Of patients in the preoperative chemotherapy group who had clinically nonorgan-confined disease, 27.1% had organ-confined disease at time of surgery compared to 1.4% of those who underwent surgery as initial therapy. CONCLUSION: In a contemporary cohort of subjects who underwent nephroureterectomy for UTUC, administration of NAC in patients with high-grade nonorgan-confined disease led to higher rates of pathologic downstaging and was associated with improved overall survival.
引用
- Khan AI, Taylor BL, Al Hussein Al Awamlh B, et al. Survival Outcomes in Neoadjuvant Chemotherapy for High-grade Upper Tract Urothelial Carcinoma: A Nationally Representative Analysis. Urology. 2020. PMID: 32896584. doi:10.1016/j.urology.2020.06.108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。